
PMC:7461420 / 37460-38595
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T201 | 550-558 | Body_part | denotes | cysteine | http://purl.org/sig/ont/fma/fma82751 |
T202 | 873-883 | Body_part | denotes | amino acid | http://purl.org/sig/ont/fma/fma82739 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T204 | 121-130 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T205 | 790-794 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T206 | 907-911 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T207 | 978-982 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T208 | 1025-1029 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T209 | 1035-1068 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T437 | 107-108 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T438 | 135-136 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T439 | 228-235 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T440 | 427-428 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T441 | 463-464 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T442 | 569-570 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T443 | 609-616 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | Peptide |
T444 | 654-655 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T445 | 704-712 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptides |
T446 | 759-766 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptide |
T447 | 873-891 | http://purl.obolibrary.org/obo/CHEBI_33708 | denotes | amino acid residue |
T448 | 873-891 | http://purl.obolibrary.org/obo/PR_000036907 | denotes | amino acid residue |
T449 | 904-905 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T450 | 951-952 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T336 | 25-40 | Chemical | denotes | Mpro inhibitors | http://purl.obolibrary.org/obo/CHEBI_147285 |
T337 | 30-40 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T338 | 62-67 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T339 | 343-353 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T340 | 470-479 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T341 | 550-558 | Chemical | denotes | cysteine | http://purl.obolibrary.org/obo/CHEBI_15356 |
T342 | 609-616 | Chemical | denotes | Peptide | http://purl.obolibrary.org/obo/CHEBI_16670 |
T343 | 617-627 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T344 | 665-670 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T345 | 694-699 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T346 | 704-712 | Chemical | denotes | peptides | http://purl.obolibrary.org/obo/CHEBI_16670 |
T347 | 759-766 | Chemical | denotes | peptide | http://purl.obolibrary.org/obo/CHEBI_16670 |
T348 | 873-891 | Chemical | denotes | amino acid residue | http://purl.obolibrary.org/obo/CHEBI_33708 |
T349 | 873-883 | Chemical | denotes | amino acid | http://purl.obolibrary.org/obo/CHEBI_33709 |
T350 | 873-878 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T351 | 879-883 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T352 | 987-1002 | Chemical | denotes | Mpro inhibitors | http://purl.obolibrary.org/obo/CHEBI_147285 |
T353 | 992-1002 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T56 | 217-226 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1153 | 25-29 | Gene | denotes | Mpro | Gene:8673700 |
1160 | 801-805 | Gene | denotes | Mpro | Gene:8673700 |
1161 | 361-365 | Gene | denotes | Mpro | Gene:8673700 |
1162 | 357-360 | Species | denotes | CoV | Tax:11118 |
1163 | 790-798 | Species | denotes | SARS‐CoV | Tax:694009 |
1164 | 550-558 | Chemical | denotes | cysteine | MESH:D003545 |
1165 | 109-130 | Disease | denotes | coronavirus infection | MESH:D018352 |
1173 | 1004-1008 | Gene | denotes | Mpro | Gene:8673700 |
1174 | 987-991 | Gene | denotes | Mpro | Gene:8673700 |
1175 | 918-922 | Gene | denotes | Mpro | Gene:8673700 |
1176 | 907-915 | Species | denotes | SARS‐CoV | Tax:694009 |
1177 | 978-986 | Species | denotes | SARS‐CoV | Tax:694009 |
1178 | 1025-1033 | Species | denotes | SARS‐CoV | Tax:694009 |
1179 | 1035-1080 | Species | denotes | severe acute respiratory syndrome coronavirus | Tax:694009 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T347 | 0-40 | Sentence | denotes | 3.1.2 Substrate‐derived Mpro inhibitors |
T348 | 41-131 | Sentence | denotes | To date, no approved drugs or vaccines are available for treating a coronavirus infection. |
T349 | 132-317 | Sentence | denotes | In a race to identify chemotherapeutic options, various approaches, such as chemical synthesis, testing of natural products, and virtual screening of compound libraries, have been used. |
T350 | 318-414 | Sentence | denotes | The systematic design of inhibitors of CoV Mpro was essentially based on the enzyme's substrate. |
T351 | 415-608 | Sentence | denotes | In general, a substrate can be transformed into a good inhibitor by modifying part of its sequence such that it binds to the catalytic cysteine in either a reversible or an irreversible manner. |
T352 | 609-746 | Sentence | denotes | Peptide inhibitors are designed by attaching a reactive group (also known as warhead group) to peptides that mimic the natural substrate. |
T353 | 747-892 | Sentence | denotes | The partial peptide substrate sequence for SARS‐CoV‐1 Mpro is mentioned in Figure 10, indicating the specific subsite of each amino acid residue. |
T354 | 893-950 | Sentence | denotes | Figure 10 A, SARS‐CoV‐1 Mpro partial substrate sequence. |
T355 | 951-1003 | Sentence | denotes | B, (Overlay) structures of SARS‐CoV Mpro inhibitors. |
T356 | 1004-1135 | Sentence | denotes | Mpro, main protease; SARS‐CoV, severe acute respiratory syndrome coronavirus [Color figure can be viewed at wileyonlinelibrary.com] |